---
title: "C&Y Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 42.1901 million yuan, an increase of 67.45%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235887183.md"
description: "According to the Zhitong Finance APP, C&Y Pharmaceutical released its 2024 annual report, stating that the company's operating income was 847 million yuan, a year-on-year increase of 5.92%. The net profit attributable to shareholders of the listed company was 42.1901 million yuan, a year-on-year increase of 67.45%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.2287 million yuan. The basic earnings per share were 0.1746 yuan"
datetime: "2025-04-14T13:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235887183.md)
  - [en](https://longbridge.com/en/news/235887183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235887183.md)
generator: "portal-rs"
---

# C&Y Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 42.1901 million yuan, an increase of 67.45%

According to the Zhitong Finance APP, C&Y Pharmaceutical (300254.SZ) released its annual report for 2024, reporting an operating income of 847 million yuan, a year-on-year increase of 5.92%. The net profit attributable to shareholders of the listed company was 42.1901 million yuan, a year-on-year increase of 67.45%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.2287 million yuan. The basic earnings per share were 0.1746 yuan

### Related Stocks

- [300254.CN](https://longbridge.com/en/quote/300254.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)
- [Ata Turizm Discloses High Non-Compliant Income Under Participation Finance Rules](https://longbridge.com/en/news/296522750.md)
- [09:18 ETThe Bybit Card Advantage: Exclusive Pre-Sale Access to Tomorrowland Brasil 2027 Tickets](https://longbridge.com/en/news/296623403.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**